S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Harpoon Therapeutics (HARP) Stock Forecast, Price & News

+0.11 (+5.58%)
(As of 05/27/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
271,695 shs
Average Volume
320,647 shs
Market Capitalization
$68.81 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Harpoon Therapeutics logo

About Harpoon Therapeutics

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.


Analyst Ratings for Harpoon Therapeutics
Harpoon Therapeutics (NASDAQ:HARP) PT Lowered to $14.00
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$23.65 million
Book Value
$1.25 per share


Net Income
$-116.72 million
Net Margins
Pretax Margin




Free Float
Market Cap
$68.81 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.06 out of 5 stars

Medical Sector

517th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

84th out of 209 stocks

Analyst Opinion: 4.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

Is Harpoon Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics
or view top-rated stocks.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Harpoon Therapeutics

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its quarterly earnings results on Thursday, March, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.20. The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $7.03 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 112.69% and a negative net margin of 366.46%.
View Harpoon Therapeutics' earnings history

What price target have analysts set for HARP?

8 Wall Street analysts have issued 1-year price targets for Harpoon Therapeutics' stock. Their forecasts range from $7.00 to $40.00. On average, they anticipate Harpoon Therapeutics' share price to reach $15.40 in the next year. This suggests a possible upside of 640.4% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Harpoon Therapeutics' key executives?
Harpoon Therapeutics' management team includes the following people:
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 55, Pay $554.55k) (LinkedIn Profile)
  • Dr. Natalie R. Sacks M.D., Chief Medical Offer (Age 57, Pay $633.35k)
  • Ms. Julie M. Eastland M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 54)
  • Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
  • Ms. Rachael Lester, Sr. VP of Bus. Devel. & Corp. Strategy
What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.47%), Vanguard Group Inc. (3.89%), Candriam Luxembourg S.C.A. (2.40%), State Street Corp (1.34%), Tekla Capital Management LLC (0.79%) and Renaissance Technologies LLC (0.64%). Company insiders that own Harpoon Therapeutics stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche and Impact Fund (Cayman) Oncology.
View institutional ownership trends for Harpoon Therapeutics

Which institutional investors are selling Harpoon Therapeutics stock?

HARP stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, Federated Hermes Inc., Candriam Luxembourg S.C.A., Panagora Asset Management Inc., Connor Clark & Lunn Investment Management Ltd., Northern Trust Corp, and Simplex Trading LLC. Company insiders that have sold Harpoon Therapeutics company stock in the last year include Ansbert Gadicke, and Holger Wesche.
View insider buying and selling activity for Harpoon Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was acquired by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Renaissance Technologies LLC, BlackRock Inc., State Street Corp, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., and Sequoia Financial Advisors LLC.
View insider buying and selling activity for Harpoon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $2.08.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics has a market capitalization of $68.81 million and generates $23.65 million in revenue each year. The company earns $-116.72 million in net income (profit) each year or ($2.31) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 99 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-7400 or via email at [email protected].

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.